Prognostic factors in early breast carcinoma

Cancer

Volumn 74, Issue 1 S, 1994, Pages 381-400

  Mansour, Edward G ^a   Ravdin, Peter M ^b   Dressier, Lynn ^c  

^a METROHEALTH MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

cathespin D; epidermal growth factor receptor; HER 2 oncogene; mutant p53; node negative breast cancer; ploidy; S phase

Indexed keywords

BLOOD CLOTTING FACTOR 8; CATHEPSIN D; CD31 ANTIGEN; CELL ADHESION MOLECULE; DNA; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; HORMONE RECEPTOR; MUTANT PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN P53; UROKINASE;

ADULT; ANGIOGENESIS; BREAST CANCER; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE S PHASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE MUTATION; HUMAN; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; ONCOGENE; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL MODEL; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; CATHEPSIN D; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECEPTORS, CELL SURFACE;

EID: 0028200888     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.2820741326     Document Type: Article

References (179)

1. A long‐term follow‐up study of survival in Stage I (T1NOMO) and Stage II (T1N1MO) breast carcinoma
2. Relation of tumor size, lymph node status and survival in 14,740 breast cancer cases
3. Adjuvant therapy for node‐negative breast cancer: an update of NSABP findings
4. Treatment of early‐stage breast cancer
5. Cancer of the breast: size of neoplasm and prognosis
6. Patterns of relapse and survival following radical mastectomy: analysis of 716 consecutive patients
7. Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases
8. The natural history of node negative breast cancer: predictors of outcome with 40 year follow‐up
9. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node‐negative breast and Bowel Project Protocol B‐06
10. Nuclear characteristics as indicators of prognosis in node‐negative breast cancer patients
11. Comparison of classic and quantitative prognostic factors in hormone receptor‐positive and hormone receptor‐negative female breast cancer
12. Tumor necrosis is a histoprognosticator for early recurrence and death in Stage II breast cancer [abstract]
13. Pregnancy associated plasma protein a and extensive necrosis: clinically significant predictors of early recurrence in Stage I estrogen receptor‐negative breast carcinoma
14. Prognostic significance of peritumoral lymphatic and blood vessel invasion in node‐negative carcinoma of the breast
15. Prognostic variables in node‐negative breast cancer: an all subset analysis
16. Risk factors for local recurrence following lumpectomy for breast cancer without radiotherapy
17. Significance of estrogen and progesterone receptors, disease‐free interval, and site of metastasis on survival of breast cancer patients
18. Prognostic value of estrogen and progesterone receptors in operable breast cancer: results of a univariate and multivariate analysis
19. Progesterone and estrogen receptor status as prognostic variables in breast cancer
20. Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node‐negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B‐06
21. Role of steroid hormones receptors as prognostic factors in primary breast cancer
22. Review: steroid receptors, cellular kinetics, and lymph node status as prognostic factors in breast cancer
23. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer
24. The long term prognostic significance of oestrogen receptor analysis in early carcinoma of the breast
25. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells
26. Immunocytochemical detection of progesterone receptor in breast cancer with monoclonal antibody: relation to biochemical assay, disease‐free survival and clinical endocrine response
27. Immunocytochemical analysis of estrogen receptors in human breast carcinomas: evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance
28. Estrogen receptor immunocytochemical assay in paraffin embedded tissue: a better gold standard?
29. The importance of normal and abnormal oestrogen receptor in breast cancer
30. Abnormal estrogen receptor in clinical breast cancer
31. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods
32. The prognostic value of immunohistochemical estrogen receptor analysis in paraffin‐embedded and frozen section vs. that of steroid binding assays
33. Immunocytochemical estrogen and progestin receptor assay in breast cancer with monoclonal antibodies: histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival
34. DNA flow cytometry in solid tumors: practical aspects and clinical applications
35. Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast
36. Association of DNA index and S‐phase fraction with prognosis of nodes positive early breast cancer
37. Are DNA flow cytometry measurements providing useful information in the management of the node negative breast cancer patient?
38. Sequential cytopunctures during pre‐operative chemotherapy for breast cancer: cytomorphologic changes, initial tumor ploidy and tumor regression
39. Sequential cyto‐punctures during pre‐operative chemotherapy for primary breast carcinoma: II. DNA flow cytometry changes during chemotherapy, tumor regression and short‐term follow‐up
40. Correlation of pre‐treatment proliferative activity with response to cytotoxic chemotherapy
41. Response to second line hormone treatment for advanced breast cancer: predictive value of ploidy determination
42. DNA flow cytometry in early breast cancer: a step in the right direction
43. The use of DNA flow cytometry to characterize breast cancer cells affected by pre‐surgical (neoadjuvant) chemotherapy
44. DNA content measurement can be obtained using archival material for DNA flow cytometry: a comparison with cytogenetic analysis in 56 pediatric solid tumor
45. Tissue specific markers in flow cytometry of urological cancers: comparing chromosomal and flow cytometric DNA analysis of bladder tumors
46. DNA content and genetic‐evaluation of human colorectal adenocarcinoma: a study by flow cytometry and cytogenetic analysis
47. Correlation of model chromosome number of cultured non‐small cell lung carcinoma with DNA index of solid tumor tissue
48. DNA ploidy and survival in breast patients
49. Flow cytometric DNA index and S‐phase fraction in breast cancer in relation to other prognostic variables and to clinical outcome
50. Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S‐phase fraction: a proposed classification of DNA histograms in breast cancer
51. Prognostic significance of DNA ploidy in a series of 690 primary breast cancer patients
52. Prognostic indicators including DNA histogram type, receptor content and staging related to human breast cancer patient survival
53. Correlation of cell cycle kinetics, hormone receptor, histopathology and nodal status in human breast cancer
54. Node negative breast cancer: prognostic subgroups defined by tumor size and DNA flow cytometry
55. The importance of DNA flow cytometry in node negative breast cancer
56. DNA flow cytometry predicts for relapse and survival in node negative breast cancer patients
57. Preliminary analysis the impact of DNA flow cytometry measurements to predict time to recurrence in the intergroups (INT 011) node negative clinical trial: an Eastern Cooperative Oncology Group Study
58. The relationship of flow cytometry to clinical and biologic characteristics in women with node negative breast cancer
59. Indicators of prognosis in node negative breast cancer
60. DNA flow cytometric analysis of primary operable breast cancer: relation of ploidy and S‐phase fraction to prognosis of patients in NSABP B‐04
61. Prognostic significance of flow cytometric DNA analyses in node negative breast patients
62. The prognostic value of flow cytometry (FCM) in Stage I and II breast cancer patients
63. Association of over‐expression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node‐negative breast cancer patients
64. Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c‐erb‐2 overexpression
65. Amplification of Her2/neu oncogene is associated with early metastasis in human breast cancer [abstract]
66. Prognostic value of Her2/neu overexpression in node‐positive breast cancer: results from two randomized adjuvant Mayo/North Central Cancer Treatment Group trials
67. Expression of the c‐erb‐3 and c‐erb‐2 gene products lacks of prognostic value in node‐negative breast carcinoma
68. Epidermal growth factor receptors and prognosis in breast cancer
69. Simulatory and inhibitory growth factors and breast cancer
70. Close similarity of epidermal growth factor receptor and c‐erbB oncogene protein sequences
71. Epidermal growth factor receptors and oestrogen receptors in human breast cancer
72. Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer
73. Epidermal growth factor receptor (EGFr): results of a 6 year follow‐up study in operable breast cancer with emphasis on the node negative subgroup
74. Epidermal growth factor receptor and other oncogenes as prognostic markers
75. Epidermal growth factor receptors and prognosis in primary breast cancer
76. Prognostic value of p53 protein and receptors for epidermal growth factor (EGR‐R), insulin‐like growth factor‐1 (IGF‐1‐R) and somatostatin (SS‐R) in patients with breast and ovarian cancer
77. Epidermal growth factors in intracranial and breast tumours: their clinical significance
78. Prognostic value of epidermal growth factor receptor in nodepositive breast cancer
79. Predictive value of EGF receptor in breast cancer
80. Transforming growth factor alpha in human mammary carcinomas and their metastases
81. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer
82. Prognostic value of epidermal growth factor receptor in a series of 303 breast cancers
83. Human breast cancer: prognostic significance of the c‐erbB2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features
84. Expression of epidermal growth factor receptor in breast carcinoma
85. Growth factor expression in breast tissue
86. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrence breast cancer
87. A secreted glycoprotein induced by estrogen in human breast cancer cell lines
88. The 52 kDa estrogen‐induced protein secreted by MCF7 cells is a lysosomal acidic protease
89. Cloning sequencing of the 52K cathepsin‐D complementary DNA of MCF7 breast cancer cells and mapping on chromosome II
90. Increased secretion, altered processing, and glycosylation of pro‐cathepsin‐D in human mammary cells
91. Phosphorylation, glycosylation, and proteolytic activity of the 52K estrogen induced protein of MCF‐7 cells
92. Overexpression and hormonal regulation of pro‐cathepsin D in mammary and endometrial cancer
93. Differential regulation of Cathepsin D by sex steroids in mammary cancer and uterine cells
94. Estrogens and growth factors induce MRNA of the pro cathepsin D secreted by breast cancer cell
95. Autocrine growth stimulation of the MCF 7 breast cancer cells by the estrogen‐regulated 52 K protein
96. Interactions of cathepsin‐D and insulin‐like growth factor‐II (IGF‐II) on the IGF‐II/mannose‐6‐phosphate receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF‐II
97. Cathepsin‐D: a protease involved in breast cancer metastasis
98. MCF‐7 mammary cancer cells respond to bFGF and internalize it following its release for extracellular matrix: a permissive role of Cathepsin‐D
99. Overexpression of transfected Cathepsin‐D in transformed cells increases their malignant phenotype and metastatic potency
100. Invirro degradation of extracellular matrix with Mw 52,000 cathepsin‐D secreted by cancer cells
101. Two‐site immunoenzymatic assay for the 52 kDa Cathepsin‐D in cytosols of breast cancer tissues
102. Association between high concentration of Mw 52,000 Cathepsin‐D and poor prognosis in primary human breast cancer
103. Cathepsin‐D: an independent prognostic factor for metastasis of breast cancer
104. La Cathepsin‐D: unfacteur pronostique independant dans le cancer du sein
105. Cathepsin‐D concentration in breast cancer cytosols: correlation with biochemical, histological and clinical findings
106. Prognostic value of total Cathepsin‐D in breast cancer
107. Prognostic relevance of Cathepsin‐D vs. oestrogen receptors in node‐negative breast cancer
108. Urikonase (uPA) and its inhibitor PAI‐1 are strong and independent prognostic factors in node‐negative breast cancer
109. Multiparametric prognostic evaluation of biological factors in primary breast cancer
110. Cathepsin‐D as a prognostic indicator for node‐negative breast cancer patients using both immunoassays and enzymatic assays
111. Prospective study on the prognostic values of Cathepsin‐D levels in breast cancer
112. Prognostic significance of Cathepsin‐D in patients with breast cancer
113. Cathepsin‐D expression detected by immunohistochemistry has independent prognostic value in axillary node‐negative breast cancer
114. Prognostic significance of immunohistochemical analysis of Cathepsin‐D in low stage breast cancer
115. Prognostic significance of the estrogen‐regulated protein, Cathepsin‐D, in breast cancer: an immunohistochemical study
116. Cathepsin‐D and prognosis in breast cancer
117. What is the evidence that tumors are angiogenesis dependent?
118. Novel growth regulatory factors and tumour angiogenesis
119. Vascular reactions of normal and malignant tumors in‐vivo: I. vascular reactions of mice to wounds and to normal and neoplastic transplants
120. Tumor behavior in isolated perfused organis: in‐vitro growth and metastasis of biopsy material in rabbit thyroid and intestinal segment
121. The prognostic significance of tumor vascularity in intermediate thickness (0.76–4.0 mm thick) skin melanoma: a quantitative histologic study
122. Tumor angiogenesis and metastasis‐correlation in invasive breast carcinoma
123. Induction of angiogenesis during the transition from hyperplasia to neoplasia
124. Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder
125. Cancer metastases and angiogenesis: an imbalance of positive and negative regulation
126. Regulation of tumor‐host interactions in breast cancer
127. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer
128. Tumor angiogenesis (TA) quantitation by factor VIII‐related antigen immunocytochemistry: a new, highly significant, and independent prognostic indicator (PI) in early stage breast carcinoma (ESBC) [abstract]
129. Angiogenesis does not predict recurrence in patients with primary breast cancer
130. An antiserum to tumour angiogenesis factor: therapeutic approach to solid tumours
131. The p53 tumour suppressor gene
132. Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer
133. Loss of chromosome 17[13 sequences and mutation of p53 in human breast carcinomas
134. Regulation of transformation and the cell cycle by p53
135. Relation between p53 overexpression and established prognostic factors in breast cancer
136. Association of over‐expression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node‐negative breast cancer patients
137. Growth arrest induced by wild‐type p53 protein blocks cells prior to or near the restriction point in late G1 phase
138. p53 Guardian of the genome
139. p53 Mutations: gains or losses?
140. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer
141. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer
142. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node‐negative breast cancer
143. Abnormal p53 immunoreactivity and prognosis in node‐negative breast carcinomas with long‐term follow‐up
144. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis
145. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer
146. The immuno response to p53 in breast cancer patients is directed against the immunodominant epitopes unrelated to the mutational hotspot
147. The p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c‐erbB‐2
148. Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours
149. Clinical relevance of the urokinase‐type and tissue‐type plasminogen activators and of their type 1 inhibitor in breast cancer
150. Complete primary structure of the human estrogen‐responsive gene (pS2) product
151. A new family of growth factor‐like peptides ‘Trefoil’ disulphide loop structures as a common feature in breast cancer associated peptide (pS2), pancreatic spasmolytic polypeptide (PSP), and frog skin peptides (spasmolysin)
152. The 5′ flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the C‐Ha‐ras oncoprotein and the c‐jun protein
153. Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node‐negative breast cancer
154. pS2 expression and response to hormonal therapy in patients with advanced breast cancer
155. Clinical breast cancer, new developments in selection and endocrine treatment of patients
156. Response of human breast cancer cells to heat shock and chemotherapeutic drugs
157. Stress response protein (srp‐27) determination in primary human breast carcinomas: clinical, histologic, and prognostic correlations
158. Heat shock protein hsp70 in patients with axillary lymph node negative breast cancer: prognostic implications
159. Confirmation of a prognostic index for patients with metastatic breast cancer treated by endocrine therapy
160. The Nottingham prognostic index in primary breast cancer
161. Proportional hazards and recursive partitioning and amalgamation analyses of the Southwest Oncology Group node‐positive adjuvant CMFVP breast cancer data base: a pilot study
162. A practical application of neural network analysis for predicting outcome of individual breast cancer patients
163. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
164. Factors predicting treatment responsiveness and prognosis in node‐negative breast cancer
165. A model of chemotherapy in node‐negative breast cancer
166. Regression models and life‐tables
167. A plain man's guide to the proportional hazards model
168. RECPAM analysis of prognostic factors in patients with Stage III breast cancer
169. Breast cancer prognostic factors: evaluation guidelines
170. Predictive value of statistical models